Future Medicine Ltd., part of Future Science Group, UK, has announced the launch of a new journal - Immunotherapy. The journal is the latest addition to Future Medicine's collection of titles addressing modern medicine and biomedical research.
Immunotherapy involves the treatment of disease through immune manipulation of the host. The valuable role of this approach in oncology is increasingly recognised alongside conventional chemo- and radio-therapies. The US Food and Drug Administration has approved the use of immunotherapy in melanoma, leukemias, lymphomas and myelomas, and in breast, cervical, ovarian, kidney, prostate and colorectal cancers.
Immunotherapy publishes reviews, original research, perspectives, commentary and news and views for interdisciplinary community with an interest in the development and clinical use of immunotherapeutics. The journal operates rigorous peer review and disclosure policies.
Prof. Yutaka Kawakami of Keio University School of Medicine, Dr Francesco M. Marincola of the National Cancer Institute and Prof. David C. Wraith of the University of Bristol will serve as Senior Editors of the journal. They will be supported by a team of eight Associate Editors, together with an Advisory Panel of more than 50 international experts.
